Email bulletin archive

Archive

December 2016

• Experimental treatments for hepatitis B
• 8-week sofosbuvir/ledipasvir treatment course
• DAA treatment in HIV/HCV co-infection
• Adherence
• Use of generic drugs for treatment of hepatitis C
• Prequalified hepatitis C rapid test
• Is this your copy of the infohep news bulletin?

November 2016

• News from the 2016 AASLD Liver Meeting
• New pangenotypic combinations
• Hepatitis C genotype 3
• Real world treatment performance matches the best clinical trial results
• Treatment scale-up and the continuum of care
• Liver cancer in people treated with direct-acting antivirals
• Hepatitis B treatment
• Generic hepatitis C drugs
• Is this your copy of the infohep news bulletin?

October 2016

• Over one million people treated for hepatitis C in low- and middle-income countries
• FDA hepatitis B reactivation warning, and hepatitis B testing for people taking hepatitis C treatment
• Hepatitis B elimination
• European action plan for the health sector response to viral hepatitis
• Reinfection risk
• Mortality risk after SVR in Scotland
• Shortening treatment
• Access to treatment
• Next month: news coverage of The Liver Meeting 2016
• Is this your copy of the infohep news bulletin?

September 2016

• New European guidelines for treatment of hepatitis C
• HCV treatment for people who inject drugs
• Alcohol and liver damage in people with hepatitis C
• Reduced fatigue after hepatitis C cure
• HCV vaccine
• Access to sofosbuvir in Ukraine
• International Viral Hepatitis Elimination Meeting 2016
• Is this your copy of the infohep news bulletin?

August 2016

• Hep-CORE study highlights gaps in European responses to viral hepatitis
• Zepatier receives EU marketing approval
• Risk factors for fibrosis progression
• Statins and progression of fibrosis in people with HIV/HCV co-infection
• Hepatitis B monitoring
• Is this your copy of the infohep news bulletin?

July 2016

• World Hepatitis Day: the launch of the NOhep movement
• Sofosbuvir/velpatasvir (Epclusa) approval in European Union and United States
• Viekirax treatment course for genotype 4 reduced in European Union
• US treatment guidelines updated
• Viral hepatitis worldwide
• Diabetes, cirrhosis and liver cancer
• Portal hypertension
• Is this your copy of the infohep news bulletin?

June 2016

• Access to hepatitis C treatment: France, Ireland and India
• Hepatitis C treatment rationing
• Global targets for the elimination of viral hepatitis
• Making hepatitis C diagnosis easier
• Is this your copy of the infohep news bulletin?

May 2016

• Governments commit to eliminating viral hepatitis by 2030 at World Health Assembly
• Two new DAA combinations set for approval in the European Union
• Hepatitis B treatment
• Hepatitis C burden of disease
• Access to hepatitis C treatment
• HIV and hepatitis C
• Experimental treatment for cirrhosis
• Head and neck cancers
• The 5th International Symposium on Hepatitis Care in Substance Users
• Is this your copy of the infohep news bulletin?

April 2016

• News from the 2016 International Liver Congress
• Infohep webinar recording
• Generic drugs for hepatitis C treatment
• New generic combination to be tested in clinical trials
• NOhep campaign
• Hepatitis C treatment highly effective in real-world settings
• Hepatitis C treatment in advanced liver disease
• Hepatitis C treatment for people whose first DAA regimen failed
• Hepatitis C genotype 3 treatment
• Reinfection and treatment in acute infection
• Pangenotypic treatment in people with HIV/HCV co-infection
• Is this your copy of the infohep news bulletin?

March 2016

• WHO guidelines update
• Counterfeit Harvoni in Europe
• Hepatitis B prevalence
• HIV and HCV co-infection
• Treatment of acute HCV infection
• Genotype 4
• HCV and lymphoma
• Screening for hepatitis C
• Upcoming event at ILC 2016: Transforming HCV Care Together
• Is this your copy of the infohep news bulletin?

February 2016

• Daklinza label expanded in Europe
• Cholesterol and liver damage in women with hepatitis C
• Cryoglobulinemia and direct-acting antivirals
• CDC warning on dialysis
• Drug pricing controversy builds in the United States
• Online treatment access data collection
• Improving referral from primary care
• Anti-microRNAs: a new experimental treatment for hepatitis C
• World Hepatitis Alliance Webinars
• Is this your copy of the infohep news bulletin?

January 2016

• Cardiovascular disease and hepatitis C
• Parkinson’s disease
• Australia hepatitis C treatment funding
• Hepatitis testing contest
• New Merck combination Zepatier approved for hepatitis C treatment in the United States
• New hepatitis C drugs in development
• Hepatitis B treatment
• Is this your copy of the infohep news bulletin?